Aberdeen Group plc Buys 69,860 Shares of Immatics N.V. $IMTX

Aberdeen Group plc raised its position in Immatics N.V. (NASDAQ:IMTX) by 9.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 789,446 shares of the company’s stock after acquiring an additional 69,860 shares during the period. Aberdeen Group plc’s holdings in Immatics were worth $6,726,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of IMTX. Bank of America Corp DE increased its position in shares of Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after purchasing an additional 2,231 shares during the period. Vanguard Personalized Indexing Management LLC lifted its position in Immatics by 8.3% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 47,635 shares of the company’s stock worth $406,000 after purchasing an additional 3,666 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Immatics by 28.7% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 31,894 shares of the company’s stock worth $172,000 after buying an additional 7,116 shares in the last quarter. Engineers Gate Manager LP bought a new stake in Immatics in the 2nd quarter valued at $124,000. Finally, Fox Run Management L.L.C. acquired a new position in shares of Immatics in the 2nd quarter valued at $136,000. Institutional investors own 64.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Immatics from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a report on Thursday, January 22nd. Leerink Partners reiterated an “outperform” rating and issued a $17.00 price objective on shares of Immatics in a research note on Thursday, December 4th. Guggenheim raised their target price on Immatics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of Immatics in a research note on Monday, November 24th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $19.20.

Immatics Price Performance

Shares of Immatics stock opened at $10.06 on Friday. The firm has a 50 day simple moving average of $9.89 and a 200 day simple moving average of $8.90. Immatics N.V. has a fifty-two week low of $3.30 and a fifty-two week high of $12.41. The firm has a market cap of $1.22 billion, a P/E ratio of -9.86 and a beta of 1.36.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.